RIMO for Opioid Use Disorder

(RIMO Trial)

Overseen By Michael L Dennis, Ph.D.

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Chestnut Health Systems

Disqualifiers: Under 18, Non-English, Non-Chicago, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

251 Participants Needed

Trial Summary

What is the purpose of this trial?

This study targets individuals in Chicago who have received naloxone administered by first responders within the past week to reverse an overdose, but who have not entered into MAT. Study participants will be recruited through partnerships with the Chicago Fire Department (CFD) and/or Police Department (CPD); first responders will be trained to seek consent from individuals who are alert and oriented after receiving naloxone for future contacts by research staff as part of the naloxone standard protocol. Those who consent will be contacted and screened for study eligibility ideally within one week of naloxone administration; eligible participants will be randomly assigned either to the control group, i.e., referral to MAT as usual, or to Recovery Initiation and Management after Overdose (RIMO), an assertive linkage and recovery support intervention. This intervention builds on an evidence-based intervention for treatment linkage, monitoring, and recovery support evaluated in 3 prior clinical trials by the study team.

Research Team

Christine E Grella, Ph.D.

Principal Investigator

Chestnut Health Systems

Eligibility Criteria

This trial is for adults in Chicago who've had an opioid overdose reversed with naloxone by first responders in the past week, are not currently in treatment, and have a positive screen for Opioid Use Disorder. They must be over 18, able to consent, and speak English.

Inclusion Criteria

Screen positive for an Opioid Use Disorder (OUD)

I was revived from an opioid overdose with naloxone by first responders within the last week.

I have not received any treatment in the last 30 days.

Exclusion Criteria

Unable to speak and understand English

Not residing in Chicago

I am unable to understand and give consent for treatment.

Treatment Details

Interventions

• Passive Referral to Treatment Control
• Recovery Initiation and Management after Overdose (RIMO)

Trial Overview The study compares two approaches: usual referral to Medication-Assisted Treatment (MAT) versus Recovery Initiation and Management after Overdose (RIMO), which includes assertive linkage to MAT and ongoing recovery support.

Participant Groups

Group I: Recovery Initiation and Management after Overdose (RIMO) Experimental Treatment 2 Interventions

Participants assigned to the RIMO arm will meet with Linkage Managers (LM), who will use motivational interviewing (MI) techniques to: 1) identify the need for treatment and barriers to going, 2) discuss with patients the benefits of their decision to go to treatment, including activities they might enjoy as well as things they do not like about their alcohol/substance use, 3) provide personalized feedback to participants about the status of their condition based on responses to the assessment instruments, 4) help participants resolve ambivalence about their use and move them toward a commitment to change by accessing additional care, 5) address existing barriers to treatment (e.g., childcare, transportation), 6) schedule a treatment appointment, and 7) facilitate medication assisted treatment re-entry and engagement.

Group II: Passive Referral Control Active Control 1 Intervention

Participants will be given information on recently expanded and publicly-funded MAT treatment in their community.

Who Is Running the Clinical Trial?

Chestnut Health Systems

Lead Sponsor

Trials

27

Recruited

24,500+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+